Full Breakdown
Triple-Therapy Regimen Eradicates HIV in Newborn Primates
8/13/2026, 8:44:05 PM
Breakthrough Study Overview
Researchers at Oregon Health & Science University (OHSU) reported that a three-part treatment administered within 72 hours of infection permanently eliminated HIV-like virus in newborn nonhuman primates. The regimen combined standard antiretroviral therapy, broadly neutralizing antibodies, and the experimental monoclonal antibody leronlimab. The work, published in *Nature Microbiology*, represents the first instance in which the virus was cleared in this model after such early intervention.
Study Design and Key Findings
- Subjects – Newborn primates were infected with a simian-human immunodeficiency virus and treated beginning within three days of exposure.
- Therapies – All three agents were given together for several weeks. Individually, each had previously failed to achieve permanent clearance.
- Outcome – Viral reservoirs were undetectable after the treatment course, indicating a functional cure in the animal model.
Co-lead author Jonah Sacha, Ph.D., noted the unexpected success: “There was no reason to think this would completely clear the virus,” — Jonah Sacha, said co-lead author . “For reasons we don't understand, HIV really wants to use CCR5 receptors to infect cells,” — Jonah Sacha, said co-lead author The team highlighted that the early window may be critical, stating they only evaluated treatment up to three days post-infection “We only tested out to three days,” — Jonah Sacha, said co-lead author .
Implications and Prospective Human Trials
More than 120,000 infants acquire HIV each year, and lifelong antiretroviral therapy remains the standard of care. If the triple-therapy approach proves safe and effective in humans, it could offer a curative strategy for newborns and, eventually, for recently exposed adults. Researchers plan to initiate first-in-human studies in adults with recent exposure before moving to pediatric trials.
Funding and Institutional Support
The project received extensive backing from the National Institutes of Health, including awards R01HD080459 (NICHD), R01AI154559, R01AI166969, R01AI129703 (National Institute of Allergy and Infectious Diseases (NIAID)), K01OD036063 (Office of the Director), and infrastructure grants P51OD011092, U42OD010426, and P51OD011107 to the Oregon and California National Primate Research Centers. The authors state that the content reflects their conclusions and not necessarily NIH policy.
Verbatim Quotes
- “There was no reason to think this would completely clear the virus,” — Jonah Sacha, co-lead author
- “For reasons we don't understand, HIV really wants to use CCR5 receptors to infect cells,” — Jonah Sacha, co-lead author
- “We only tested out to three days,” — Jonah Sacha, co-lead author
